Table 1 Comparison of FISH results by 2013 and 2018 ASCO/CAP guidelines

From: Implementation of the 2018 American Society of Clinical Oncology/College of American Pathologists Guidelines on HER2/neu Assessment by FISH in breast cancers: predicted impact in a single institutional cohort

2013 guidelines

2018 guidelines, No. (%)

Total

Negative

Positive

Negative

1178 (76.4%)

0

1178 (76.4%)

Equivocal

91 (5.9%)

4 (0.2%)

95 (6.2%)

Positive

70 (4.5%)

199 (12.9%)

269 (17.4%)

Total

1339 (86.8%)

203 (13.2%)

1542 (100%)

Back to article page